{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:10:17Z","timestamp":1791670217128,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100005937","name":"Cheng Hsin General Hospital","doi-asserted-by":"crossref","award":["CHGH109-(IP)1-01"],"award-info":[{"award-number":["CHGH109-(IP)1-01"]}],"id":[{"id":"10.13039\/501100005937","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005937","name":"Cheng Hsin General Hospital","doi-asserted-by":"crossref","award":["CHGH109-(IP)1-02"],"award-info":[{"award-number":["CHGH109-(IP)1-02"]}],"id":[{"id":"10.13039\/501100005937","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Although the beneficial effect of sacubitril\/valsartan (SAC\/VAL) compared to enalapril was consistent across ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy (NICM) groups, the PARADIGM-HF study did not analyse the effect of ventricular remodelling on patients with different aetiologies, which may affect clinical treatment outcomes. This study aimed to compare left ventricular ejection fraction (LVEF) following SAC\/VAL treatment and its association with clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A total of 1576 patients were analysed. Patients were grouped by LVEF changes following SAC\/VAL treatment for 8-month period. LVEF improvement \u226515% was defined as \u2018significant improvement\u2019, and &amp;lt;5% or worse was classified as \u2018lack of improvement\u2019. The primary outcome was a composite of cardiovascular death and unplanned hospitalization for heart failure. Patients with NICM had lower baseline LVEF but improvement was significantly greater comparing to those with ICM (baseline 28.0\u2009\u00b1\u20097.7% vs. 30.1\u2009\u00b1\u20097.1%, P\u2009&amp;lt;\u20090.001, LVEF increase of 11.1\u2009\u00b1\u200912.6% vs. 6.7\u2009\u00b1\u200910.2%, P\u2009&amp;lt;\u20090.001). The effect of functional improvement of SAC\/VAL on NICM patients showed bimodal distribution. Primary endpoints were inversely associated with LVEF changes in NICM patients: adjusted hazard ratio was 0.42 [95% confidence interval (CI) 0.31\u20130.58, P\u2009&amp;lt;\u20090.001] for NICM patients with significant improvement, and was 1.73 (95% CI 1.38\u20132.16, P\u2009&amp;lt;\u20090.001) for NICM patients but lack of improvement. Primary endpoints of ICM patients did not demonstrate an association with LVEF changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with NICM had higher degree of LVEF improvement than those with ICM following SAC\/VAL treatment, and significant improvement of LVEF in NICM patients indicates favourable outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa125","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T19:38:12Z","timestamp":1602790692000},"page":"118-129","source":"Crossref","is-referenced-by-count":24,"title":["Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril\/valsartan treatment"],"prefix":"10.1093","volume":"8","author":[{"given":"Ying-Hsiang","family":"Lee","sequence":"first","affiliation":[{"name":"Cardiovascular Center, MacKay Memorial Hospital, No. 9, Section 2, Zhongshan N Rd, Zhongshan District, Taipei City, 104 Taiwan"},{"name":"Department of Medicine, Mackay Medical College, No. 46, Section 3, Zhongzheng Road, Sanzhi District, New Taipei City, 252 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ru","family":"Chiou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mackay Medical College, No. 46, Section 3, Zhongzheng Road, Sanzhi District, New Taipei City, 252 Taiwan"},{"name":"Division of Cardiology, Taitung MacKay Memorial Hospital, No. 1, Lane 303, Zhangsha Street, Taitung City, Taitung County, 950 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yi","family":"Hsu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, School of Medicine, National Yang Ming University, No. 155, Section 2, Linong St, Beitou District, Taipei City, 112 Taiwan"},{"name":"Division of Cardiology and Cardiovascular Research Center, Taipei Medical University Hospital; Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Heart Institute, Taipei Medical University, No. 252, Wuxing Street, Xinyi District, Taipei City, 110 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Lin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mackay Medical College, No. 46, Section 3, Zhongzheng Road, Sanzhi District, New Taipei City, 252 Taiwan"},{"name":"Division of Cardiology, Department of Internal Medicine, Hsinchu MacKay Memorial Hospital, No. 690, Section 2, Guangfu Road, East District, Hsinchu City, 300 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Wen","family":"Liang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, E-Da Hospital, No. 1, Yida Road, Yanchao District Kaohsiung City, 827 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Po","family":"Chung","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, School of Medicine, National Yang Ming University, No. 155, Section 2, Linong St, Beitou District, Taipei City, 112 Taiwan"},{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Beitou District, Taipei City, 112 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Te","family":"Liao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Chi-Mei Medical Center, No. 901, Zhonghua Road, Yongkang District, Tainan City, 710 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Section 2, Chenggong Road, Neihu District, Taipei City, 114, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-7739","authenticated-orcid":false,"given":"Hung-Yu","family":"Chang","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, School of Medicine, National Yang Ming University, No. 155, Section 2, Linong St, Beitou District, Taipei City, 112 Taiwan"},{"name":"Heart Center, Cheng Hsin General Hospital, No.45 Cheng-Hsin Street, 112 Beitou, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"2022030710593530800_pvaa125-B1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ehjcvp\/pvu006","article-title":"Pharmacotherapy in heart failure with reduced ejection fraction during the last 20 years, and the way ahead for precision medicine","volume":"1","author":"Zannad","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022030710593530800_pvaa125-B2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jacc.2006.11.041","article-title":"Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials","volume":"49","author":"Frazier","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022030710593530800_pvaa125-B3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/eurjhf\/hfs026","article-title":"Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis","volume":"14","author":"Mart\u00ednez-Sell\u00e9s","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2022030710593530800_pvaa125-B4","first-page":"264","article-title":"Prognostic impact over time of ischaemic heart disease vs. non-ischaemic heart disease in heart failure","volume":"7","author":"Silverdal","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2022030710593530800_pvaa125-B5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2022030710593530800_pvaa125-B6","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2022030710593530800_pvaa125-B7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2022030710593530800_pvaa125-B8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"2022030710593530800_pvaa125-B9","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.jacc.2010.05.055","article-title":"Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study","volume":"56","author":"Linde","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022030710593530800_pvaa125-B10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jchf.2019.06.004","article-title":"Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction","volume":"7","author":"Aimo","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022030710593530800_pvaa125-B11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022030710593530800_pvaa125-B12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2019.02.015","article-title":"Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF","volume":"7","author":"Balmforth","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022030710593530800_pvaa125-B13","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"2022030710593530800_pvaa125-B14","first-page":"244","article-title":"2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure","volume":"35","author":"Wang","year":"2019","journal-title":"Acta Cardiol Sin"},{"key":"2022030710593530800_pvaa125-B15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2022030710593530800_pvaa125-B16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41540-017-0013-4","article-title":"Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: a systems biology approach","volume":"3","author":"Iborra-Egea","year":"2017","journal-title":"NPJ Syst Biol Appl"},{"key":"2022030710593530800_pvaa125-B17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2018.05.042","article-title":"Dynamic trajectories of left ventricular ejection fraction in heart failure","volume":"72","author":"Lup\u00f3n","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022030710593530800_pvaa125-B18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0735-1097(02)01726-6","article-title":"Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis","volume":"39","author":"Allman","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2022030710593530800_pvaa125-B19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijcard.2015.01.025","article-title":"Myocardial viability for decision-making concerning revascularization in patients with left ventricular dysfunction and coronary artery disease: a meta-analysis of non-randomized and randomized studies","volume":"182","author":"Orlandini","year":"2015","journal-title":"Int J Cardiol"},{"key":"2022030710593530800_pvaa125-B20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jacc.2011.09.073","article-title":"Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy","volume":"59","author":"Gerber","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022030710593530800_pvaa125-B21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.amjcard.2010.03.014","article-title":"Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability","volume":"106","author":"Sawada","year":"2010","journal-title":"Am J Cardiol"},{"key":"2022030710593530800_pvaa125-B22","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"key":"2022030710593530800_pvaa125-B23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa1807365","article-title":"Myocardial viability and long-term outcomes in ischemic cardiomyopathy","volume":"381","author":"Panza","year":"2019","journal-title":"N Engl J Med"},{"key":"2022030710593530800_pvaa125-B24","doi-asserted-by":"crossref","first-page":"e12435","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"2022030710593530800_pvaa125-B25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijcard.2010.01.011","article-title":"Heart failure etiology impacts survival of patients with heart failure","volume":"149","author":"Pecini","year":"2011","journal-title":"Int J Cardiol"},{"key":"2022030710593530800_pvaa125-B26","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/01.CIR.100.12.1298","article-title":"Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome","volume":"100","author":"Samady","year":"1999","journal-title":"Circulation"},{"key":"2022030710593530800_pvaa125-B27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jacc.2014.04.064","article-title":"Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction","volume":"64","author":"Panza","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022030710593530800_pvaa125-B28"},{"key":"2022030710593530800_pvaa125-B29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijcard.2010.10.125","article-title":"Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL","volume":"146","author":"Ceconi","year":"2011","journal-title":"Int J Cardiol"},{"key":"2022030710593530800_pvaa125-B30","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"key":"2022030710593530800_pvaa125-B31","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta- blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2022030710593530800_pvaa125-B32","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2022030710593530800_pvaa125-B33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022030710593530800_pvaa125-B34","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2022030710593530800_pvaa125-B35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.amjcard.2005.01.030","article-title":"Long-term effects of carvedilol or metoprolol on left ventricular function in ischemic and nonischemic cardiomyopathy","volume":"95","author":"Green","year":"2005","journal-title":"Am J Cardiol"},{"key":"2022030710593530800_pvaa125-B36","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.amjcard.2017.01.023","article-title":"Relation of myocardial contrast-enhanced T1 mapping by cardiac magnetic resonance to left ventricular reverse remodeling after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy","volume":"119","author":"H\u00f6ke","year":"2017","journal-title":"Am J Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa125\/34602669\/pvaa125.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/2\/118\/42750698\/pvaa125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/2\/118\/42750698\/pvaa125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T11:01:04Z","timestamp":1646650864000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/2\/118\/5942978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,29]]},"published-print":{"date-parts":[[2022,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa125","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2020,10,29]]}}}